ECO 2026 12 - 15 May 2026

CagriSema 2.4 mg/2.4 mg Improves Metabolic Syndrome in Adults With Overweight or Obesity, Without Type 2 Diabetes: A Post hoc Analysis of REDEFINE 1

Authors :

Matthias Blüher¹; Kasper Adelborg²; Melanie J. Davies³; Ildiko Lingvay⁴; Christian Bøge Lyndgaard²; Rasmus Sørrig²; John P. H. Wilding⁵; Ania M. Jastreboff⁶

Affiliations

View Details Hide Details

Download .PDF

Keywords

Congress poster

CagriSema

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

CagriSema 2.4 mg/2.4 mg Improves Metabolic Syndrome in Adults With Overweight or Obesity, Without Type 2 Diabetes: A Post hoc Analysis of REDEFINE 1